Neurotech International Ltd has released a press release.
Phase II/III ASD Trial Successfully Meets Primary Endpoint
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
In the deck
Earlier from Neurotech International
- Last Patient Completes Treatment in NTIASD2 Clinical Trial
- Rett Syndrome Patients to Receive NTI164 for 52 Weeks
- PANDAS/PANS Patients Show Continued Clinical Improvement
- Neurotech Receives Additional HREC Approval in Autism
- NTI Receives HREC Approval for Cerebral Palsy Trial
Later from Neurotech International
- Neurotech Completes $10 Million Capital Raise
- Rett Syndrome Phase I/II trial shows significant benefits
- Further clinical benefit at 52 weeks in PANDAS/PANS patients
- Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
- Significant improvement in Autism patients at 12 weeks
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International